|
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|
|
Ovarian Carcinoma
|
0.500 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Ovarian Carcinoma
|
0.500 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.
|
10880552 |
2000 |
|
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
BRCA1 is a tumor suppressor gene that is responsible for hereditary breast and ovarian carcinoma syndrome.
|
11443609 |
2001 |
|
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
BRCA-1 and BRCA-2 are tumor suppressor genes in familial breast-ovarian carcinoma syndrome.
|
11550149 |
2001 |
|
Ovarian Carcinoma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma--an Indian study.
|
24385383 |
2014 |
|
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
BRCA1/2 pathogenic (P) and likely pathogenic (LP) germline variants are frequent among patients with ovarian carcinoma.
|
30606148 |
2019 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BRCA1 5382insC mutation in sporadic and familial breast and ovarian carcinoma in Scotland.
|
9155062 |
1997 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A high proportion of young women with invasive OC have mutations in BRCA1, and a smaller fraction have mutations in other known OC genes.
|
26718727 |
2016 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A patient with breast carcinoma diagnosed at the age of 30 years and ovarian carcinoma diagnosed at the age of 41 years was found to have germline mutations in both the BRCA1 and the BRCA2 genes.
|
9790802 |
1998 |
|
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
|
31653147 |
2019 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Alteration of expression of the tumor suppressor gene BRCA-1 has been widely studied in breast and ovarian carcinoma.
|
30446260 |
2019 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
|
28882436 |
2017 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
At the time of salpingo-oophorectomy, five of 58 BRCA1 carriers (8.6%) were diagnosed with an occult carcinoma: two fallopian tube carcinomas, two ovarian carcinomas and one case was defined as a fallopian tube/ovarian carcinoma.
|
15083174 |
2004 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BRCA2 mutations were less common than BRCA1 mutations in families with any history of ovarian carcinoma.
|
10717622 |
2000 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
|
29233532 |
2018 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Eligible patients are premenopausal BRCA1/2 mutation carriers after completing childbearing without (a history of) ovarian carcinoma.
|
26286255 |
2015 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Four carriers of pathogenic mutations in both BRCA1 and BRCA2 were identified among women who underwent genetic counseling for hereditary susceptibility to breast and ovarian carcinoma at three different Italian institutions.
|
20373018 |
2010 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germ-line mutations in the BRCA1 and BRCA2 genes confer a predisposition to breast as well as ovarian carcinoma.
|
9661879 |
1998 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in the BRCA1 and BRCA2 genes are associated with an inherited predisposition to breast and ovarian carcinoma, and specific mutations in these genes are found at increased frequency in certain populations.
|
12879478 |
2003 |
|
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here, we show that the p53-related gene p73, encoding a proapoptotic protein that is linked to chemosensitivity in many settings, is upregulated through a novel epigenetic mechanism in both human and murine models of BRCA1-associated ovarian carcinoma.
|
20807817 |
2010 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In women with breast cancer, mutations in BRCA1 and BRCA2 were associated with a 10-fold increased risk of subsequent ovarian carcinoma (P = .005).
|
9667259 |
1998 |
|
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Increased cell survival by inhibition of BRCA1 using an antisense approach in an estrogen responsive ovarian carcinoma cell line.
|
11056686 |
2000 |
|
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.
|
19060844 |
2009 |